NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN) Margin Slippage Tests Bullish Earnings Growth Narrative
Regeneron Pharmaceuticals (REGN) has put up another busy quarter, with Q3 FY 2025 revenue of US$3.8b and basic EPS of US$14.09 alongside net income of US$1,460m, all against a backdrop where trailing 12 month EPS sits at US$43.30 on revenue of US$14.2b. The company has seen revenue move from US$3.5b in Q2 FY 2024 to US$3.8b in Q3 FY 2025, while quarterly EPS has shifted from US$13.25 to US$14.09 over the same span. This gives investors a clear look at how top line and per share earnings have...